DIACARTA

Company Overview

DiaCarta Inc. is developing and commercializing molecular diagnostics. The company offers a range of services including testing at its CLIA-certified lab, NGS, companion diagnostics and CAR-T immunotherapy.

Many of DiaCarta’s diagnostic assays run on formalin-fixed, paraffin-embedded tissue, but the company is moving towards offering liquid biopsy versions of these tests. The company’s ColoScape test uses QClamp XNA-based clamping technology and a real-time PCR analysis method. The assay is designed to screen for 20 colorectal cancer mutations.

DiaCarta began offering this test in a liquid biopsy format in 2018. The test now can use either FFPE, stool or blood as the sample. This compares with its main competition, Cologuard (Exact Sciences), which needs human stool as a sample and has a longer turnaround time of two weeks versus less than three days for ColoScape.

ColoScape is used for triage (patients who have a positive fecal hemoglobin test and who also test positive using ColoScape would move to a colonoscopy), recurrence and monitoring applications.

DiaCarta is developing other liquid biopsy kits for testing mutations in EGFR, BRAF and PIK3CA.

The company operates a CLIA laboratory, which provides a pan-cancer liquid biopsy test, OptiSeq. This test uses NGS to analyze for 2,900 hotspots in 65 oncogenes and tumor suppressor genes.

Company's Business Segments

• Products : Diacarta generates revenue from products in Oncology, Infectious Diseases, OTC/POC Tests and Accessories, Research Use Products, Consumables.
• Clinical Services : Cancer Progression and Therapy Response Monitoring, Colorectal Cancer, Bladder Cancer, Urinary Tract Infection (UTI), In Vitro Fertilization (IVF), Infectious Diseases.